Risankizumab (Skyrizi) prior authorization at Kaiser Permanente
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Kaiser Permanente requires prior-authorization documentation for Risankizumab (Skyrizi): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Kaiser Permanente reviews Risankizumab (Skyrizi) prior authorizations against its medical policy . Kaiser Permanente-specific context: Integrated delivery system — care + insurance coordinated. California DMHC oversight is unique. CA IMR (Independent Medical Review) is a powerful external review track for Kaiser denials.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Kaiser Permanente's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Out-of-network non-emergency denials
- Specialty referrals delayed
- Mental health access (DMHC complaints common)
Risankizumab (Skyrizi)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring TNF and/or ustekinumab first
- Crohn's indication denial despite FDA approval (2022)
- UC indication denial despite FDA approval (2024)
- Specialty pharmacy network restriction
Brand: Skyrizi. IL-23 inhibitor approved for plaque psoriasis, PsA, Crohn's disease (2022), and ulcerative colitis (June 2024). AbbVie's heir-apparent post-Humira.
Manufacturer patient-assistance program: AbbVie Complete — relevant when a Kaiser Permanente denial sticks and the patient needs bridge access while appealing.
How Kaiser Permanente approaches Biologic drugs (mAbs and biosimilars) PAs
For Risankizumab, check whether the current Kaiser Permanente Biologic drugs (mAbs and biosimilars) policy cites specialty referrals delayed. Pharmacy-benefit review for Risankizumab at Kaiser Permanente is routed through Kaiser Permanente Pharmacy (integrated in-house). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Kaiser Permanente; if denied, use the filing date and route printed on that denial notice. Kaiser Permanente's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Kaiser Permanente is domiciled in CA, so unresolved appeals escalate to the CA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://providers.kaiserpermanente.org) with the same packet plus an applicable, current clinical source supporting Risankizumab (Skyrizi)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Kaiser Permanente denial on DenialHelp.
Contact Kaiser Permanente
- Provider portal: https://providers.kaiserpermanente.org
Frequently asked questions
What documentation does Kaiser Permanente need for Risankizumab (Skyrizi) prior auth?
Kaiser Permanente's typical PA packet for Risankizumab (Skyrizi): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Kaiser Permanente?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Risankizumab (Skyrizi) at Kaiser Permanente?
Preparation scenarios to check against the current notice and policy include: Out-of-network non-emergency denials; Specialty referrals delayed; Mental health access (DMHC complaints common). These are not measured frequency claims. For Risankizumab (Skyrizi), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Kaiser Permanente typically require before approving Risankizumab?
Kaiser Permanente's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For Risankizumab, attach the specific disease-activity instrument Kaiser Permanente accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Kaiser Permanente Pharmacy (integrated in-house). External-review escalation for Kaiser Permanente fully-insured policies sits with the CA insurance department.
How do I prep for a peer-to-peer with Kaiser Permanente on Risankizumab (Skyrizi)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Risankizumab (Skyrizi) PA packet
Open ApprovalHelp — generate a Risankizumab (Skyrizi) prior-auth packet tailored to Kaiser Permanente's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com